Department of Cell Growth and Tumor Regulation, ProteoMedicine Research Center, Ehime University.
J Biochem. 2012 Nov;152(5):381-2. doi: 10.1093/jb/mvs096. Epub 2012 Aug 25.
Transmembrane proteins on the cell surface dynamically move in the sea of phospholipids. During the process of cell adhesion, migration and proliferation, physical interactions of transmembrane proteins such as integrins and receptor tyrosine kinases (RTKs) on the cell surface constantly vary. The enzyme-mediated activation of radical source (EMARS) reaction, a newly developed biochemical labelling method for cell surface molecules clustering in living cells, is a powerful tool for capturing new partners even if they only transiently cluster with the interesting target molecules during a biological process such as cell adhesion, migration, invasion or proliferation. The EMARS reaction was applied for investigating new partner RTKs to an adhesion molecule integrin β1, resulting in the identification of ErbB4. This study further reveals that the association of integrin β1 and ErbB4 occurs in a spatiotemporally regulated manner at an early phase within 2 h of seeding cells and that this induced activation of ErbB4 tyrosine kinase, which is required for integrin-dependent cell migration (Yamashita, R., Kotani, N., Ishiura, Y., Higahsiyama, S., and Honke, K. Spatiotemporally-regulated interaction between b1 integrin and ErbB4 that is involved in fibronectin-dependent cell migration. J Biochem 2011;149:347-355). The EMARS reaction is also currently lighting up intriguing new partners of target therapeutic molecules.
细胞膜表面的跨膜蛋白在磷脂海中动态移动。在细胞黏附、迁移和增殖过程中,细胞膜表面整合素和受体酪氨酸激酶(RTKs)等跨膜蛋白的物理相互作用不断变化。酶介导的自由基源(EMARS)反应是一种新开发的用于活细胞中细胞表面分子聚类的生化标记方法,它是一种强大的工具,可以捕捉新的伴侣,即使它们在细胞黏附、迁移、侵袭或增殖等生物学过程中仅与感兴趣的靶分子短暂聚类。该 EMARS 反应应用于研究新的伴侣 RTKs 与黏附分子整合素β1,结果鉴定出 ErbB4。这项研究进一步揭示了整合素β1和 ErbB4 的关联以时空调节的方式发生在细胞接种后 2 小时内的早期阶段,并且这种诱导的 ErbB4 酪氨酸激酶的激活对于整合素依赖性细胞迁移是必需的(Yamashita,R.,Kotani,N.,Ishiura,Y.,Higahsiyama,S.,and Honke,K. 参与纤维连接蛋白依赖性细胞迁移的 b1 整合素和 ErbB4 之间的时空调节相互作用。J Biochem 2011;149:347-355)。EMARS 反应目前也为靶向治疗分子的有趣新伴侣带来了新的启示。